Next Article in Journal
Interaction between Hepatitis B Virus and Toll-Like Receptors: Current Status and Potential Therapeutic Use for Chronic Hepatitis B
Next Article in Special Issue
Meningococcal Vaccines: Current Status and Emerging Strategies
Previous Article in Journal
Acknowledgement to Reviewers of Vaccines in 2017
Previous Article in Special Issue
A Burkholderia pseudomallei Outer Membrane Vesicle Vaccine Provides Cross Protection against Inhalational Glanders in Mice and Non-Human Primates
Open AccessArticle

Outer Membrane Vesicle Vaccines from Biosafe Surrogates Prevent Acute Lethal Glanders in Mice

Department of Infectious Diseases and Immunology, College of Veterinary Medicine; University of Florida, Gainesville, FL 32608, USA
Emerging Pathogens Institute, University of Florida, Gainesville, FL 32610, USA
Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville, FL 32603, USA
Author to whom correspondence should be addressed.
Vaccines 2018, 6(1), 5;
Received: 26 November 2017 / Revised: 4 January 2018 / Accepted: 6 January 2018 / Published: 10 January 2018
(This article belongs to the Collection Vaccines against Chronic and Persistent Bacterial Infections)
Burkholderia mallei is a host-adapted Gram-negative mammalian pathogen that causes the severe disease glanders. Glanders can manifest as a rapid acute progression or a chronic debilitating syndrome primarily affecting solipeds and humans in close association with infected animals. In USA, B. mallei is classified as one of the most important bacterial biothreat agents. Presently, there is no licensed glanders vaccine available for humans or animals. In this work, outer membrane vesicles (OMVs) were isolated from three attenuated biosafe bacterial strains, Burkholderia pseudomallei Bp82, B. thailandensis E555, and B. thailandensis TxDOH and used to vaccinate mice. B. thailandensis OMVs induced significantly higher antibody responses that were investigated. B. mallei specific serum antibody responses were of higher magnitude in mice vaccinated with B. thailandensis OMVs compared to levels in mice vaccinated with B. pseudomallei OMVs. OMVs derived from biosafe strains protected mice from acute lethal glanders with vesicles from the two B. thailandensis strains affording significant protection (>90%) up to 35 days post-infection with some up to 60 days. Organ loads from 35-day survivors indicated bacteria colonization of the lungs, liver, and spleen while those from 60 days had high CFUs in the spleens. The highest antibody producing vaccine (B. thailandensis E555 OMVs) also protected C57BL/6 mice from acute inhalational glanders with evidence of full protection. View Full-Text
Keywords: glanders; outer membrane vesicles; biosafe vaccines glanders; outer membrane vesicles; biosafe vaccines
Show Figures

Figure 1

MDPI and ACS Style

Norris, M.H.; Khan, M.S.R.; Chirakul, S.; Schweizer, H.P.; Tuanyok, A. Outer Membrane Vesicle Vaccines from Biosafe Surrogates Prevent Acute Lethal Glanders in Mice. Vaccines 2018, 6, 5.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop